MCID: SYN007
MIFTS: 54

Synovitis

Categories: Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Synovitis

MalaCards integrated aliases for Synovitis:

Name: Synovitis 11 19 75 53 5 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:2703
MeSH 43 D013585
NCIt 49 C50766
SNOMED-CT 68 268092005
UMLS 71 C0039103

Summaries for Synovitis

Disease Ontology: 11 A connective tissue disease that results in inflammation located in synovial membrane that lines a synovial joint which causes pain and swelling.

MalaCards based summary: Synovitis is related to pigmented villonodular synovitis and sapho syndrome, and has symptoms including arthralgia, myalgia and metatarsalgia. An important gene associated with Synovitis is RELN (Reelin), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Rituximab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include synovial membrane, bone marrow and bone, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Synovitis is the medical term for inflammation of the synovial membrane. This membrane lines joints that... more...

Related Diseases for Synovitis

Diseases related to Synovitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1048)
# Related Disease Score Top Affiliating Genes
1 pigmented villonodular synovitis 32.9 TNFSF11 CRP CD68 CD163
2 sapho syndrome 32.6 TNF IL1RN IL18 CXCL8 CRP
3 tenosynovitis 32.1 TNF MMP3 IL6 IL1B CRP
4 reactive arthritis 31.9 TNF MMP1 CRP COMP
5 hyperostosis 31.4 MMP13 IL18 CXCL8
6 temporal arteritis 31.3 TNF MMP3 IL6 IL1RN IL1B IL18
7 acne 31.1 TNF MMP1 IL6 IL1RN IL1B CXCL8
8 bursitis 31.1 TNF IL6 IL1B CRP
9 spondyloarthropathy 1 31.1 TNFSF11 TNF MMP3 IL6 IL1RN IL1B
10 spondylitis 31.0 TNFSF11 TNF IL6 IL1B CRP
11 carpal tunnel syndrome 30.9 IL6 IL1B COMP
12 septic arthritis 30.9 TNFSF11 TNF MMP3 MMP13 IL6 IL1B
13 juvenile rheumatoid arthritis 30.9 TNF IL6 IL1RN IL1B IL18 CRP
14 gout 30.9 TNF IL6 IL1B IL18 CXCL8 CRP
15 chondrocalcinosis 30.9 MMP3 MMP1 IL1B CRP
16 pustulosis of palm and sole 30.8 TNF IL1RN CXCL8 CRP
17 osteomyelitis 30.8 TNFSF11 TNF MMP1 IL6 IL1RN IL1B
18 psoriatic arthritis 30.8 TNFSF11 TNF MMP3 MMP1 IL6 IL1RN
19 bone inflammation disease 30.8 TNFSF11 TNF MMP3 MMP13 MMP1 IL6
20 cartilage disease 30.7 TNF PRG4 MMP3 MMP13 IL6 IL1B
21 osteoarthritis 30.7 TNFSF11 TNF PRG4 MMP3 MMP13 MMP1
22 spondylarthropathy 30.6 TNF CRP CD163
23 arthropathy 30.6 TNFSF11 TNF PRG4 MMP3 MMP13 MMP1
24 uveitis 30.6 TNF IL6 IL1B ICAM1 CXCL8
25 enchondromatosis, multiple, ollier type 30.6 TNFSF11 MMP13 COL2A1
26 temporomandibular joint anomaly 30.6 TNFSF11 MMP3
27 ankylosis 30.6 TNFSF11 TNF CRP
28 systemic scleroderma 30.6 TNF IL6 IL1B CXCL8 CRP
29 dermatitis 30.5 TNF IL6 IL1B IL18 CXCL8
30 pain agnosia 30.5 TNF IL6 IL1B CRP
31 rubella 30.5 TNF IL6 IL1B
32 exanthem 30.5 TNF IL6 IL1B IL18 CXCL8 CRP
33 lyme disease 30.4 TNF IL6 IL1B IL18 CRP
34 malignant giant cell tumor 30.4 TNFSF11 CD68
35 psoriasis 30.4 VCAM1 TNF IL6 IL1B IL18 ICAM1
36 brucellosis 30.4 TNF IL6 IL1RN IL18 CXCL8 CRP
37 neutrophilic dermatosis, acute febrile 30.4 TNF IL1B CXCL8 CRP
38 complex regional pain syndrome 30.4 TNF IL6 IL1B
39 osteochondrosis 30.4 MMP13 CRP COMP COL2A1
40 amyloidosis 30.4 TNF IL6 IL1B CRP
41 leprosy 3 30.4 TNF IL6 IL1B IL18 CXCL8
42 chronic recurrent multifocal osteomyelitis 30.4 TNFSF11 TNF IL6 IL1RN IL1B CRP
43 familial mediterranean fever 30.4 TNF IL6 IL1RN IL1B IL18 CXCL8
44 rheumatoid arthritis 30.3 VCAM1 TNFSF11 TNF PRG4 MMP3 MMP13
45 spondyloarthropathy 30.3 TNFSF11 TNF IL6 IL1B CXCL8 CRP
46 cryoglobulinemia 30.3 TNF IL6 IL1B
47 fibromyalgia 30.3 TNF IL6 IL1B CXCL8 CRP
48 autoimmune disease 30.3 VCAM1 TNF IL6 IL1RN IL1B IL18
49 crohn's disease 30.3 TNF IL6 IL1B IL18 CXCL8 CRP
50 rheumatic fever 30.3 TNF IL6 ICAM1

Graphical network of the top 20 diseases related to Synovitis:



Diseases related to Synovitis

Symptoms & Phenotypes for Synovitis

UMLS symptoms related to Synovitis:


arthralgia; myalgia; metatarsalgia

GenomeRNAi Phenotypes related to Synovitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 CD163 CD68 COL2A1 COMP CRP CXCL8
2 no effect GR00402-S-2 10.17 CD68 COL2A1 CRP ICAM1 IL18 IL1B

MGI Mouse Phenotypes related to Synovitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 CD163 COL2A1 COMP CRP ICAM1 IL18
2 growth/size/body region MP:0005378 10.21 COL2A1 COMP ICAM1 IL18 IL1B IL1RN
3 immune system MP:0005387 10.19 CD163 CD68 COL2A1 COMP CRP ICAM1
4 cardiovascular system MP:0005385 10.13 CD163 COL2A1 COMP CRP ICAM1 IL18
5 muscle MP:0005369 10.03 CD163 COMP ICAM1 IL18 IL6 RELN
6 skeleton MP:0005390 9.9 CD68 COL2A1 COMP IL1B IL1RN IL6
7 hematopoietic system MP:0005397 9.77 CD163 CD68 ICAM1 IL18 IL1B IL1RN
8 integument MP:0010771 9.32 ICAM1 IL18 IL1B IL1RN IL6 MMP13

Drugs & Therapeutics for Synovitis

Drugs for Synovitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rituximab Approved Phase 4 174722-31-7
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
4
Upadacitinib Approved, Investigational Phase 4 1310726-60-3 76829165 58557659
5 Antineoplastic Agents, Immunological Phase 4
6 Melanocyte-Stimulating Hormones Phase 4
7 Adrenocorticotropic Hormone Phase 4
8
beta-Endorphin Phase 4
9 Hormones Phase 4
10 Hormone Antagonists Phase 4
11
Triamcinolone hexacetonide Phase 4
12
Triamcinolone diacetate Phase 4
13
Triamcinolone Acetonide Phase 4 6436
14 glucocorticoids Phase 4
15 Anti-Inflammatory Agents Phase 4
16 BAX 855 Phase 4
17 Factor VIII Phase 4
18 Coagulants Phase 4
19 Tumor Necrosis Factor Inhibitors Phase 4
20 Janus Kinase Inhibitors Phase 4
21 Protein Kinase Inhibitors Phase 4
22
Etanercept Approved, Investigational Phase 3 185243-69-0
23
Abatacept Approved Phase 3 332348-12-6
24
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
25
Certolizumab pegol Approved Phase 3 428863-50-7
26
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
27 Anti-Inflammatory Agents, Non-Steroidal Phase 3
28 Gastrointestinal Agents Phase 3
29 Anti-Arrhythmia Agents Phase 3
30 Sodium Channel Blockers Phase 3
31 Diuretics, Potassium Sparing Phase 3
32
Chondroitin Phase 3 9007-27-6 14389182
33 Immune Checkpoint Inhibitors Phase 3
34 Anti-Asthmatic Agents Phase 3
35 Respiratory System Agents Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 Analgesics Phase 3
38 Neurotransmitter Agents Phase 3
39 Psychotropic Drugs Phase 3
40 Hallucinogens Phase 3
41
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
42
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
43
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
44
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
45
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
47
Ascorbic acid Approved, Nutraceutical Phase 2 50-81-7 54676860 54670067 5785
48
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
49 Grapefruit Seed Extract Phase 2
50 Vitamins Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
2 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Unknown status NCT02437461 Phase 4 Triamcinolone hexacetonide
3 Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging Completed NCT01948388 Phase 4 corticotrophin 80 units
4 Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis. Completed NCT00502853 Phase 4 rituximab [MabThera/Rituxan];Methotrexate
5 A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs Completed NCT01034397 Phase 4 tocilizumab [RoActemra/Actemra];placebo;non-biological DMARDs
6 Injection After Arthroscopic Partial Meniscectomy Enrolling by invitation NCT04641351 Phase 4 Zilretta Injectable Product or Placebo
7 Intensive Replacement Treatment in Haemophilia Patients With Synovitis Not yet recruiting NCT04784988 Phase 4 Adynovate;plasma derived or recombinant products containing FVIII
8 Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. Not yet recruiting NCT05153200 Phase 4 Upadacitinib;Adalimumab
9 Adipose Derived Stromal Cell Transplantation as an Adjunct to Arthroscopy in Treatment of Effusion Synovitis of the Early Degenerative Knee Suspended NCT03922490 Phase 4
10 Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs Withdrawn NCT01878318 Phase 4 methotrexate;tocilizumab [RoActemra/Actemra]
11 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Completed NCT02371369 Phase 3 Pexidartinib;Placebo
12 Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee Completed NCT00604539 Phase 3 Chondroitin sulphate (Condrosan);Placebo
13 A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate Completed NCT00420199 Phase 3 Abatacept;Placebo
14 Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis Completed NCT00522184 Phase 3
15 Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA) Completed NCT00996606 Phase 3 DMARDs;Tocilizumab
16 The Role of Intra-articular Injection of Autologous Platelet Rich Plasma Versus Corticosteriods in Treatment of Synovitis in Lumbar Facet Joint Disease Completed NCT04860531 Phase 3 Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma;Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone
17 The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients Completed NCT01213017 Phase 3 certolizumab pegol
18 A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION) Recruiting NCT05059262 Phase 3 vimseltinib;Placebo
19 Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial Recruiting NCT05335252 Phase 3 Dronabinol;Placebo
20 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo
21 A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT) Completed NCT02471716 Phase 1, Phase 2
22 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
23 Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence Completed NCT00678782 Phase 2 etanercept;placebo
24 Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy Completed NCT00001677 Phase 2 Methotrexate;Fludarabine
25 A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties Completed NCT01272830 Phase 2 Placebo;Apatone®B
26 Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis Completed NCT00425932 Phase 2
27 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Recruiting NCT03069469 Phase 1, Phase 2 DCC-3014
28 MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE Recruiting NCT03355482 Phase 2 Methylprednisolone;Placebos
29 A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor Active, not recruiting NCT04938180 Phase 2
30 An Adaptive, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee Active, not recruiting NCT04731675 Phase 2
31 A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Active, not recruiting NCT01207492 Phase 2 nilotinib
32 A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor Not yet recruiting NCT05349643 Phase 2
33 Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint Withdrawn NCT01471418 Phase 2 PET/CT with 18-FDG
34 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT) Terminated NCT02673736 Phase 1 PLX73086
35 A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Terminated NCT02060305 Phase 1 Bevacizumab intra-articular injection
36 Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children in a Retrospective Case Series Unknown status NCT03507933
37 Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography Unknown status NCT00903903
38 Does Synovitis Affect Treatment Efficacy in Intra-articular Injection Therapy to Osteoarthritis Unknown status NCT03167333 platelet rich plasma;Hyaluronic acid
39 Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis Unknown status NCT01731262
40 Characterizing Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) With 68Ga-FAPI PET/CT Unknown status NCT04596462 Early Phase 1 68Ga-FAPI
41 A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis Unknown status NCT02339636
42 Correlation of "Painless" Synovitis With Clinical, Laboratory and Radiological (X-ray, Sonography) Finds in Patients With Longstanding Rheumatoid Arthritis (RA). Unknown status NCT01639287
43 The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission.Preliminary Study Unknown status NCT01050010
44 Efficacy of Kinesio Tape in the Treatment of Medial Plica Syndrome - A Prospective Study Unknown status NCT04085497
45 Using Magnetic Resonance Imaging and DL Methods to Explore the Diagnosis and Clinical Prognosis of Joint Synovitis. Completed NCT04952896
46 Screening of Specific Genes for Pigmented Villous Nodular Synovitis Completed NCT04955535
47 Comparison of the Frequency of Subclinic Synovitis in the Distal Interphalangeal Joints of the Hand in Psoriasis Patients Completed NCT04750993
48 Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients Completed NCT00001679
49 A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome Completed NCT00890058
50 Prospective Analgesic Compound Efficacy (PACE) Study Completed NCT02403687 baclofen 2%;Bupivacaine hydrochloride 1%;Cyclobenzaprine hydrochloride 2%;Diclofenac Sodium 3%;Flurbiprofen 10%;Gabapentin 6%;Ketamine 10%;Lidocaine 2%;Prilocaine 2.5%;Meloxicam 0.09%;Sumatriptan 5%;Tizanidine 0.1%;Topiramate 2.5%;Capsaicin, USP 0.0375%;Menthol, NF 5.00 %

Search NIH Clinical Center for Synovitis

Genetic Tests for Synovitis

Anatomical Context for Synovitis

Organs/tissues related to Synovitis:

FMA: Synovial Membrane
MalaCards : Bone Marrow, Bone, T Cells, Neutrophil, Endothelial, Lymph Node, Skin

Publications for Synovitis

Articles related to Synovitis:

(show top 50) (show all 12172)
# Title Authors PMID Year
1
Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. 53 62
20436079 2010
2
Haem oxygenase-1 down-regulates high mobility group box 1 and matrix metalloproteinases in osteoarthritic synoviocytes. 53 62
20110250 2010
3
TNF-alpha-induced aquaporin 9 in synoviocytes from patients with OA and RA. 53 62
20181673 2010
4
Expression of aquaporin 1 (AQP1) in human synovitis. 53 62
20149606 2010
5
Immunologic rheumatic disorders. 53 62
20176259 2010
6
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. 53 62
20181277 2010
7
Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. 53 62
19565512 2009
8
Interleukin-6 as a key player in systemic inflammation and joint destruction. 53 62
19189867 2009
9
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. 53 62
19333931 2009
10
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. 53 62
19883500 2009
11
[Content of C-reactive protein, interleukin-1, interleukin-6 and interleukin-1 receptor antagonist in the blood of patients with early osteoarthrosis of the knee joints]. 53 62
19663194 2009
12
Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. 53 62
18762862 2009
13
Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. 53 62
18975340 2008
14
Association of body fat with C-reactive protein in rheumatoid arthritis. 53 62
18759279 2008
15
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? 53 62
18234715 2008
16
Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. 53 62
18578976 2008
17
Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. 53 62
18310134 2008
18
Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. 53 62
17976692 2008
19
Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. 53 62
18565244 2008
20
Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. 53 62
18311806 2008
21
The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. 53 62
18311801 2008
22
[Cartilage oligomeric matrix protein, a possible marker of synovitis in early knee joint osteoarthrosis]. 53 62
19177799 2008
23
Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study. 53 62
18346273 2008
24
Anti-inflammatory activity of chondroitin sulfate. 53 62
18667340 2008
25
Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. 53 62
18582368 2008
26
Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. 53 62
17918786 2007
27
Expression of receptor activator of nuclear factor-kappaB ligand in synovial tissue: comparison with degradation of articular cartilage in temporomandibular joint disorders. 53 62
17560137 2007
28
[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein]. 53 62
17642234 2007
29
Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. 53 62
17425385 2007
30
Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. 53 62
17289161 2007
31
Comparison of taurine chloramine and taurine bromamine effects on rheumatoid arthritis synoviocytes. 53 62
16868648 2007
32
Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. 53 62
17397533 2007
33
Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study. 53 62
16670155 2006
34
Inflammation-induced bone loss: can it be prevented? 53 62
17288976 2006
35
Pathogenesis of spondyloarthritis: insights from synovial membrane studies. 53 62
16839506 2006
36
Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. 53 62
16901276 2006
37
Anti-TNF and sex hormones. 53 62
16855166 2006
38
The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. 53 62
16891219 2006
39
Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis? 53 62
16205926 2006
40
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 53 62
16542506 2006
41
The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. 53 62
17177994 2006
42
Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. 53 62
16282041 2005
43
Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. 53 62
15672235 2005
44
Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis. 53 62
15843449 2005
45
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 53 62
16329106 2005
46
Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. 53 62
16076882 2005
47
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. 53 62
16142748 2005
48
Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. 53 62
16142858 2005
49
Immunoglobulin G from anti-glucose-6-phosphate isomerase antibodies positive patient with rheumatoid arthritis induces synovitis in cynomolgus monkeys. 53 62
16137614 2005
50
Tumor necrosis factor-alpha increases chemokine gene expression and production in synovial fibroblasts from human temporomandibular joint. 53 62
15946184 2005

Variations for Synovitis

ClinVar genetic disease variations for Synovitis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RELN NM_005045.4(RELN):c.7456A>G (p.Ser2486Gly) SNV Pathogenic
684430 rs760019076 GRCh37: 7:103163872-103163872
GRCh38: 7:103523425-103523425

Expression for Synovitis

Search GEO for disease gene expression data for Synovitis.

Pathways for Synovitis

Pathways related to Synovitis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CD68 COL2A1 CRP CXCL8 ICAM1 IL18
2
Show member pathways
13.65 TNFSF11 TNF MMP3 MMP1 IL6 IL1RN
3
Show member pathways
13.43 COL2A1 CXCL8 ICAM1 MMP1 MMP13 MMP3
4
Show member pathways
13.26 VCAM1 TNFSF11 TNF MMP3 MMP1 LTB
5
Show member pathways
12.78 VCAM1 MMP3 MMP13 MMP1 ICAM1 COMP
6
Show member pathways
12.65 CXCL8 IL18 IL1B IL1RN IL6 TNF
7 12.6 VCAM1 TNFSF11 TNF IL1RN IL1B
8
Show member pathways
12.54 TNF IL6 IL1B IL18 CXCL8
9
Show member pathways
12.45 CXCL8 IL1B IL1RN IL6 TNF
10
Show member pathways
12.32 TNF IL6 IL1B CXCL8
11
Show member pathways
12.32 CXCL8 IL6 MMP1 MMP13 MMP3 TNF
12
Show member pathways
12.22 VCAM1 ICAM1 COMP COL2A1
13 12.2 TNF IL6 IL1RN IL1B CXCL8
14 12.07 VCAM1 MMP3 MMP13 ICAM1
15 12.04 TNF IL6 CD68 CD163
16 11.97 TNF LTB IL6 IL1B ICAM1 CXCL8
17
Show member pathways
11.96 IL18 IL1B IL6 TNF
18
Show member pathways
11.96 MMP1 MMP13 MMP3 TNF
19 11.92 VCAM1 MMP3 IL6 CXCL8
20
Show member pathways
11.88 IL6 ICAM1 CXCL8
21 11.87 TNF IL1B CXCL8
22 11.84 TNF LTB IL1B IL18
23
Show member pathways
11.82 VCAM1 LTB CXCL8
24 11.82 MMP1 IL6 ICAM1 CXCL8
25 11.79 TNF IL6 IL1B CD163
26 11.79 TNF MMP1 IL6 IL1B ICAM1 CXCL8
27
Show member pathways
11.78 IL6 CXCL8 CRP
28 11.74 TNF IL6 CRP
29 11.73 MMP1 IL6 CXCL8
30 11.71 TNF IL6 IL1B CXCL8
31 11.7 IL1B IL6 LTB TNF TNFSF11
32 11.69 CXCL8 ICAM1 IL6 TNF VCAM1
33
Show member pathways
11.66 TNF IL6 IL18
34 11.66 MMP3 MMP13 MMP1 CXCL8 COL2A1
35 11.63 MMP1 IL6 CXCL8
36 11.6 ICAM1 TNF VCAM1
37 11.59 TNF IL6 CXCL8
38 11.56 TNF IL1B IL18
39 11.55 TNFSF11 TNF IL6 IL1B
40 11.54 VCAM1 TNF IL6
41 11.52 TNFSF11 IL6 CRP
42 11.51 VCAM1 ICAM1 CXCL8
43 11.4 MMP1 IL6 CXCL8
44 11.4 TNF IL6 IL1B
45 11.39 TNF IL6 IL1B IL18
46 11.37 TNF IL6 IL1RN IL1B IL18 ICAM1
47
Show member pathways
11.36 VCAM1 TNF MMP3 MMP1 IL6 IL1B
48 11.32 TNF IL6 IL1B CXCL8
49 11.31 TNF IL6 IL1B
50 11.31 VCAM1 TNF MMP3 MMP1 IL6 IL1B

GO Terms for Synovitis

Cellular components related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.13 CD163 COL2A1 COMP CRP CXCL8 IL18
2 extracellular matrix GO:0031012 9.93 RELN MMP3 MMP13 MMP1 COMP COL2A1
3 extracellular space GO:0005615 9.85 COL2A1 COMP CRP CXCL8 ICAM1 IL18

Biological processes related to Synovitis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.31 CRP CXCL8 IL18 IL1B IL6 TNF
2 positive regulation of DNA-binding transcription factor activity GO:0051091 10.19 IL1B IL6 TNF TNFSF11
3 extracellular matrix organization GO:0030198 10.18 TNF MMP3 MMP13 MMP1 COL2A1
4 cellular response to lipopolysaccharide GO:0071222 10.16 TNF IL6 IL1B CXCL8 CD68
5 regulation of insulin secretion GO:0050796 10.11 TNF IL6 IL1B
6 extracellular matrix disassembly GO:0022617 10.11 MMP3 MMP13 MMP1
7 cellular response to amyloid-beta GO:1904646 10.1 VCAM1 TNF ICAM1
8 defense response to Gram-positive bacterium GO:0050830 10.1 TNF IL6 IL1B IL18 CRP
9 collagen catabolic process GO:0030574 10.09 MMP1 MMP13 MMP3
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.09 IL18 IL1B IL6 TNF TNFSF11
11 lipopolysaccharide-mediated signaling pathway GO:0031663 10.08 TNF IL1B IL18
12 acute-phase response GO:0006953 10.07 IL6 CRP CD163
13 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.05 TNF IL1B COL2A1
14 inflammatory response GO:0006954 10.03 CD163 CRP CXCL8 IL18 IL1B IL1RN
15 negative regulation of neurogenesis GO:0050768 10.01 IL1B IL6 TNF
16 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.93 IL6 IL1RN
17 positive regulation of glial cell proliferation GO:0060252 9.93 TNF IL6 IL1B
18 positive regulation of fever generation GO:0031622 9.91 TNF IL1B
19 membrane to membrane docking GO:0022614 9.91 VCAM1 ICAM1
20 positive regulation of chemokine production GO:0032722 9.91 TNF IL6 IL1B IL18
21 sequestering of triglyceride GO:0030730 9.87 TNF IL1B
22 leukocyte migration GO:0050900 9.86 TNF IL1B ICAM1
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.85 TNF IL1B
24 negative regulation of lipid storage GO:0010888 9.8 CRP IL6 TNF
25 immune response GO:0006955 9.8 TNFSF11 TNF PRG4 LTB IL6 IL1RN
26 vascular endothelial growth factor production GO:0010573 9.73 TNF IL6 IL1B
27 signaling GO:0023052 9.7 TNFSF11 TNF LTB
28 positive regulation of neuroinflammatory response GO:0150078 9.23 TNF IL6 IL1B IL18

Molecular functions related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.5 TNFSF11 TNF LTB IL6 IL1RN IL1B
2 tumor necrosis factor receptor binding GO:0005164 9.43 LTB TNF TNFSF11

Sources for Synovitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....